uniQure NVMEX:QUREN 29 FCF Margin % is -1,077.58% as of Mar. 2026. GuruFocus rates MEX:QUREN with a GF Score™ of 29/100 and a GF Value™ of MXN99.43 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 959 Biotechnology companies, uniQure NV ranks worse than 79.04% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. uniQure NV's Free Cash Flow for the
three
months ended in Mar. 2026 was MXN-692.2 Mil. uniQure NV's Revenue for the
three
months ended in Mar. 2026 was MXN64.2 Mil. Therefore, uniQure NV's FCF Margin % for the quarter that ended in Mar. 2026 was -1,077.58%.
The historical rank and industry rank for uniQure NV's FCF Margin % or its related term are showing as below:
MEX:QUREN'
s FCF Margin % Range Over the Past 10 Years
Min: -1446.66 Med: -622.21 Max: 51.63
Current: -948.14
During the past 13 years, the highest FCF Margin % of uniQure NV was 51.63%. The lowest was -1446.66%. And the median was -622.21%.
MEX:QUREN's FCF Margin % is ranked worse than 79.04% of 959
companies
in the Biotechnology industry
Industry Median: -84.65
vs MEX:QUREN: -948.14
uniQure NV FCF Margin % Related Terms
uniQure NV FCF Margin % Historical Data
* Premium members only.
The historical data trend for uniQure NV's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:QUREN vs NVAX, HRMY, IOVA: FCF Margin % Comparison
For the Biotechnology subindustry, uniQure NV's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
uniQure NV FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, uniQure NV's FCF Margin % distribution charts can be found below:
* The bar in red indicates where uniQure NV's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
uniQure NV (MEX:QUREN) has a FCF Margin % of -1,077.58% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on uniQure NV and its competitors. According to the industry distribution chart, uniQure NV ranks #758 out of 959 companies in the Biotechnology industry, placing it in the top 79%.
Is uniQure NV's FCF Margin % too high?
uniQure NV's current FCF Margin % is -1,077.58%. Based on the distribution chart, uniQure NV ranks #758 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, uniQure NV has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does uniQure NV's FCF Margin % compare to NVAX and HRMY?
According to the Biotechnology industry distribution chart, uniQure NV ranks #758 out of 959 companies for FCF Margin %. This places uniQure NV in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on uniQure NV and its competitors. uniQure NV's current FCF Margin % is -1,077.58%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is uniQure NV stock overvalued right now?
Based on GuruFocus' analysis, uniQure NV (MEX:QUREN) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN99.43, compared to a current price of MXN795.45 — trading 700% above its estimated fair value. The current FCF Margin % is -1,077.58%. uniQure NV's overall GF Score™ is 29/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For uniQure NV (MEX:QUREN), the current FCF Margin % is -1,077.58% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is uniQure NV (MEX:QUREN) Overvalued in 2026?
Based on GuruFocus' analysis, uniQure NV stock appears to be overvalued.
The current stock price of MXN795.45 is trading 700% above its estimated GF Value™ of MXN99.43.
GuruFocus considers uniQure NV to be Significantly Overvalued.
Key valuation signals for MEX:QUREN:
FCF Margin %: -1,077.58%
GF Value™: MXN99.43 vs. price of MXN795.45 (700% above fair value)
No single metric tells the full story. See the MEX:QUREN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
29GF Score
Get the complete analysis for MEX:QUREN
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:QUREN has been successfully added to your 
